<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Kisspeptin/GPR54 Agonist Peptide Analog Shows Promise as a Medical Castration Compound</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">TAK-488 is an oligopeptide analog of kisspeptin, which is a hypothalmic protein that activates the G-protein-coupled receptor GPR54 [Navarro VM, Tena-Sempere M. Nat Rev Endocrinol 2011]. A randomized, placebo-controlled Phase 1 study that used various, continuously administered doses of TAK-488 has demonstrated its safety, tolerability, and effectiveness in suppressing pituitary secretion of luteinizing hormone and follicular-stimulating hormone, which are key in the regulation of testosterone synthesis. Accordingly, serum testosterone declined to below castrate levels in most of the healthy male volunteers.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>